Navigation Links
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
Date:5/8/2008

ward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Professor of Engineering at the University of Delaware, ... problems in energy engineering, environmental sustainability and electronics. ... porous rock with a well-defined, crystalline structure. At ... precisely decided that zeolites can separate molecules with ... angstrom (one-tenth of a nanometer), making them useful ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... Jerusalem, July 21, 2010 -- Scientists from the Hebrew ... is possible to greatly expand the memory capacity of ... on silica nanoparticles combined with protein molecules obtained from ... say, they have developed an alternative avenue to miniaturize ...
... 21 The Lucian Leape Institute at the National ... special evening program at its Third Annual Forum & ... Blumenthal, M.D., M.P.P., will deliver a keynote address at the ... patient safety lever and the focus placed on its development ...
... DALLAS , July ... report "Bioinformatics Market - Advanced Technologies, Global,Forecast and Winning ... bioinformatics market is,expected to reach a $8.3 billion ... from,2009-2014. While knowledge management formed the largest submarket is ...
Cached Biology Technology:Protein from poplar trees can be used to greatly increase computer capacity 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 3David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 4MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 2MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 3MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 4
(Date:7/24/2014)... that successfully treated lupus in mice, a biomedical engineer at ... expand his research to a new version of the drug ... diseases., Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed ... in Arthritis Research & Therapy outlining the use of a ... the number of cases of lupus-related kidney disease., He now ...
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... been abused or neglected early in life are ... health problems. In a new study, scientists have ... activated, which has implications for children,s long-term development. ... individual characteristics and genetics interacted with that child,s ... problems emerge. In the new study, researchers were ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... reason for the weight-conscious to drink fat free milk,at breakfast ... of,the American Journal of Clinical Nutrition . Researchers in ... increase,satiety, or a feeling of fullness, and led to decreased ... drink. The milk drinkers ate,about 50 fewer calories (or nearly ...
... Notch signaling helps determine the fate of a number ... humans. In an article that appears in the current issue ... of Medicine report that a new finding about the Notch ... fly could explain the mystery behind an immunological disorder called ...
... Dissolved organic carbon (DOC) losses from tile drains ... This is particularly important in the eastern corn belt ... management practices, such as manure application, can play a ... organic carbon is applied to or injected into the ...
Cached Biology News:Drinking milk in the morning may help stave off lunchtime hunger 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3Study of agricultural watersheds and carbon losses 2
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
... monoclonal [YPF19] to Yersinia pestis ... Yersinia pestis . Immunogen: ... Yersinia pestis vaccine strain EV76. ... recognises Y.pestis F1 capsular antigen. There ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: